Major Depressive Disorder with Psychotic Symptoms (MDD-PS)
Conditions
Interventions
Control group:Aripiprazole combined with Brexpiprazole analog and Escitalopram
Study group:Brepiprazole in combination with Aripiprazole mimic and Escitalopram
Sponsors
Shandong mental health center
Eligibility
Sex/Gender
All
Age
13 Years to 17 Years
Inclusion criteria
Inclusion criteria: 1.Meeting DSM-5 criteria for MDD-P (with psychotic features, confirmed by SCID-5-P); 2.Adolescents aged 13-17; 3.CGI-S >= 4, with a current episode lasting >= 4 weeks; 4.Obtain informed consent from the patient and their legal guardians;
Exclusion criteria
Exclusion criteria: 1.Subjects with a concomitant serious somatic disease; 2.Alcohol or other psychoactive substance abusers; 3.Presence of intellectual developmental disorders; 4.Those with other mental disorders (such as bipolar disorder, schizophrenia); 5.Previously known allergy to the study drug; 6.Other conditions that the investigator deems unsuitable for enrollment; 7.Pregnant and lactating women;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Psychotic Symptoms Rating Scale;Hamilton Depression Scale, HAMD-24;Hamilton Anxiety Scale,HAMA;Montgomery-Asberg Depression Rating Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Barnes akathisia rating scale, BARS;Global Assessment Function;Clinical Global Impression.CGI;Treatment Emergent Symptom Scale,TESS;Self-Rating Anxiety Scale; | — |
Countries
China
Contacts
Public ContactXin Li
Shandong mental health center
Outcome results
None listed